Stemline Therapeutics (STML) Misses Q2 EPS by 17c

Stemline Therapeutics (NASDAQ: STML) reported Q2 EPS of ($0.58), $0.17 worse than the analyst estimate of ($0.41).

For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49